Skip to main content

Table 3 Selected neuropsychiatric adverse events (NP-AEs) after the use of dolutegravir (DTG) among the uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) genotypes

From: Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1

  −/− −/*28 −/*6 *28/*28 *6/*28 *6/*6
n = 51 n = 18 n = 23 n = 3 n = 4 n = 8
Insomnia (n) 4 4 2 1 1 2
Headache (n) 2 2 3 1 0 1
Dizziness (n) 5 3 0 0 1 0
Restlessness (n) 2 0 1 0 1 0
Anxiety (n) 0 0 1 0 1 0
At least one NP-AEs (n, %) 11 (22%) 8 (44%) 7 (30%) 2 (67%) 3 (75%) 3 (38%)